Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · MEDANTA

MEDANTA

HealthcareHealthcare Services₹38578 cr market cap
₹1478.30 ▲ +2.9% today As of 19 Nov 2026
52-week low ₹961.1052-week high ₹1508.90

-4.8% from the 52-week high · +49.5% above the low

Global Health Ltd. engages in the provision of healthcare, pathology, and other medical services. The company is headquartered in New Delhi, Delhi. The company went IPO on 2022-11-16. Medanta delivers advanced, end-to-end healthcare in Delhi, Gurugram, Indore, Ranchi, Patna and Lucknow through its network of five hospitals, six Mediclinic, diagnostic laboratories, homecare and telemedicine services. The company provides treatments for coronary artery disease, head and neck cancer, acute myeloid leukemia, epilepsy, hip fracture, Parkinson's disease, refractive error, prostate cancer, chronic kidney disease, cerebral stroke, sepsis, liver cirrhosis, rheumatoid, arthritis, hypertension, diabetes, bronchial asthma, stomach cancer, and chronic otitis media. Medanta specializes in cardiac surgery, nephrology, urology, andrology, dermatology, ophthalmology, radiology and imaging, dental sciences, and interventional cardiology, among others. Its facilities and services include medicine delivery, air ambulance, patient support services, and others.

The short version. MEDANTA reported revenue of ₹1,469 crore for Sep 2026, up 33.7% from a year earlier. Net profit was ₹219 crore (up 38.6% year on year). Return on equity was 14.1% in Mar 2026. Promoter holding was 33.0% in Sep 2026, down 0.03 points over 8 quarters.

1 · The price

How has the stock traded?

MEDANTA trades 4.8% below its 52-week high and 49.5% above its 52-week low.

Change over period: —

1M+16.0%
3M+1.4%
6M+15.8%
1Y+20.8%

2 · The business

Is it growing?

Sales, year on year+33.7%

Sep 2026 revenue of ₹1,469 cr.

Profit, year on year+38.6%

Sep 2026 net profit of ₹219 cr.

Net margin14.9%

0.5 pts higher than a year earlier.

3-year growth19.5% profit

Revenue compounded at 17.8% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue146913041159112110991031931943
Net profit21915914495158159101143
Net margin %14.912.212.48.514.415.410.915.1
EPS (₹)8.155.95.363.545.895.923.785.32

Annual

FY2026FY2025FY2024FY2023
Revenue4410369232752694
Net profit556481478326
Net margin %12.613.014.612.1
EPS (₹)20.717.9217.8112.16

3 · The quality

How well does it turn capital into profit?

Return on equity was 14.1% in Mar 2026; debt to equity is 0.30.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %14.114.216.513.4
Return on capital %15.017.219.014.9
EBITDA margin %22.624.026.124.5
Net margin %12.312.814.311.8

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR17.8%—
Profit CAGR19.5%—
Debt to equity0.30
Interest cover10.0x
Current ratio2.67
P/E ratio62.9

4 · The owners

Who holds it, and are they adding?

Promoter holding33.0%

Down 0.03 pts over 8 quarters.

Foreign institutions9.91%

Down 2.56 pts over 8 quarters.

Domestic institutions17.01%

Up 6.5 pts over 8 quarters.

Mutual fund schemes152

+36 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter33.0333.0333.0133.0133.0133.0133.033.0-0.03
FII12.4711.7611.5411.410.5310.159.469.91-2.56
DII10.5111.9312.212.9814.014.7616.8917.01+6.5
Public43.9843.2843.1942.5542.442.040.5639.97-4.01

Mutual fund holdings · Oct 2026

152 schemes hold this stock

116 the month before.

  • Invesco India Pharma and Healthcare Fund5.96% of NAV
  • Groww BSE Hospitals ETF5.2% of NAV
  • Invesco India Focused Fund4.1% of NAV
  • Invesco India Mid cap Fund3.67% of NAV
  • UTI - Healthcare Fund3.37% of NAV
  • HSBC Consumption Fund3.0% of NAV
  • Motilal Oswal Innovation Opportunities Fund2.91% of NAV
  • ITI Pharma and Healthcare Fund2.65% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for MEDANTA are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about MEDANTA

What is the MEDANTA share price?

MEDANTA (MEDANTA) last closed at ₹1,478.30, up 2.9% on the day. Its 52-week range is ₹961.10 to ₹1,508.90.

What is the market cap of MEDANTA?

MEDANTA has a market capitalisation of about ₹38,578 crore. Its price-to-earnings ratio is 62.9.

How are MEDANTA's latest results?

MEDANTA reported revenue of ₹1,469 crore for Sep 2026, up 33.7% from a year earlier. Net profit was ₹219 crore (up 38.6% year on year). Return on equity was 14.1% in Mar 2026. Promoter holding was 33.0% in Sep 2026, down 0.03 points over 8 quarters.

Who owns MEDANTA?

As of Sep 2026, shareholding was: Promoter 33.0%, FII 9.91%, DII 17.01%, Public 39.97%.

How many mutual funds hold MEDANTA?

152 mutual fund schemes held MEDANTA in October 2026. That compares with 116 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 22 Aug 2025 · Final Dividend - Rs. 0.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.